1. 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. (10th December 2020) Authors: Davar, Diwakar; Simonelli, Matteo; Gutierrez, Martin; Calvo, Emiliano; Melear, Jason; Piha-Paul, Sarina; Richards, Donald; Dallos, Matthew; Parameswaran, Janaki; Kumar, Vinit; Zhao, Xiaochen; Dutta, Santanu; Melero, Ignacio Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. (9th November 2020) Authors: Davar, Diwakar; Simonelli, Matteo; Gutierrez, Martin; Calvo, Emiliano; Melear, Jason; Piha-Paul, Sarina; Richards, Donald; Dallos, Matthew; Parameswaran, Janaki; Kumar, Vinit; Zhao, Xiaochen; Dutta, Santanu; Melero, Ignacio Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗